Advertisement

Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution

Published:November 27, 2015DOI:https://doi.org/10.1016/j.clcc.2015.11.005

      Abstract

      Background

      The combination drug TAS-102 is a novel oral nucleoside antitumor agent containing trifluridine and tipiracil hydrochloride, which prevents the degradation of trifluridine. The global phase III RECOURSE trial (Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies) demonstrated that TAS-102 prolonged the survival of patients with metastatic colorectal cancer (mCRC) whose disease progressed after standard therapies. TAS-102 was first approved in Japan in March 2014, and little is known about its safety and efficacy in clinical practice, especially for mCRC patients with previous regorafenib treatment.

      Patients and Methods

      We investigated the safety and efficacy of TAS-102 monotherapy in clinical practice for patients with mCRC refractory to standard therapies who were treated from May 2014 to January 2015.

      Results

      A total of 55 patients received TAS-102. The Eastern Cooperative Oncology Group performance status was 0, 1, and 2 in 41.8%, 47.3%, and 10.9% of patients. Of the 55 patients, 32 (58.2%) had been treated with regorafenib before receiving TAS-102. The median progression-free survival and overall survival was 2.0 months and 5.3 months, respectively. Emergency hospitalization was required for 23.6% of the patients during TAS-102 treatment, although most of the events (76.9%) were disease-related. The most common grade 3 or 4 adverse events were neutropenia (41.8%), leukopenia (27.2%), anemia (23.6%), febrile neutropenia (5.5%), and fatigue (3.6%). The frequency of grade ≥ 3 events was not significantly increased among the patients who had compared with those who had not received regorafenib. The progression-free survival (median 2.1 vs. 2.0 months) and overall survival (median 6.2 vs. 4.7 months) were similar for the 2 subgroups.

      Conclusion

      The safety and efficacy of TAS-102 monotherapy in clinical practice were maintained, irrespective of previous regorafenib treatment.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Colorectal Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • International Agency for Research on Cancer
        GLOBOCAN.
        2012 (Available at:) (Accessed December 21, 2015)
        • Venook A.P.
        • Niedzwiecki D.
        • Lenz H.J.
        • et al.
        CALGB/SWOG 80405: phase III trial of FOLFIRI or FOLFOX with bevacizumab or cetuximab for patients w/KRAS wild-type untreated metastatic adenocarcinoma of the colon or rectum.
        J Clin Oncol. 2014; 32 (abstract LBA3): 5s
        • Saltz L.B.
        • Clarkes S.
        • Diaz-Rubio E.
        • et al.
        Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
        J Clin Oncol. 2008; 26: 2013-2019
        • Jonker D.J.
        • O'Callaghan C.J.
        • Karapetis C.S.
        • et al.
        Cetuximab for the treatment of colorectal cancer.
        N Engl J Med. 2007; 357: 2040-2048
        • Van Cutsem E.
        • Kohne C.H.
        • Hitre E.
        • et al.
        Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
        N Engl J Med. 2009; 360: 1408-1417
        • Van Cutsem E.
        • Peeters M.
        • Siena S.
        • et al.
        Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.
        J Clin Oncol. 2007; 25: 1658-1664
        • Douillard J.Y.
        • Siena S.
        • Cassidy J.
        • et al.
        Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
        J Clin Oncol. 2010; 28: 4697-4705
        • Van Cutsem E.
        • Tabernero J.
        • Lakomy R.
        • et al.
        Addition of aflibercept to fluorouracil, leucovorin and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
        J Clin Oncol. 2012; 30: 3499-3506
        • Grothey A.
        • Van Cutsem E.
        • Sobrero A.
        • et al.
        Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicenter, randomized, placebo-controlled, phase 3 trial.
        Lancet. 2013; 381: 303-312
        • Li J.
        • Qin S.
        • Xu R.
        • et al.
        Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomized, double-blind, placebo-controlled, phase 3 trial.
        Lancet Oncol. 2015; 16: 619-629
        • Yamazaki K.
        • Nagase M.
        • Tamagawa H.
        • et al.
        A randomized phase III trial of mFOLFOX6 plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment for metastatic colorectal cancer: West Japan Oncology Group study 4407G (WJOG4407G).
        J Clin Oncol. 2014; 32 (abstract 3534): 5s
        • Tanaka N.
        • Sakamoto K.
        • Okabe H.
        • et al.
        Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models.
        Oncol Rep. 2014; 32: 2319-2326
        • Doi T.
        • Ohtsu A.
        • Yoshino T.
        • et al.
        Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumors.
        Br J Cancer. 2012; 107: 429-434
        • Yoshino T.
        • Mizunuma N.
        • Yamazaki K.
        • et al.
        TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomized, placebo-controlled phase 2 trial.
        Lancet Oncol. 2012; 13: 993-1001
        • Bendell J.C.
        • Rosen L.S.
        • Mayer R.J.
        • et al.
        Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer.
        Cancer Chemother Pharmacol. 2015; 76: 925-932
        • Mayer R.J.
        • Van Cutsem E.
        • Falcone A.
        • et al.
        Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
        N Engl J Med. 2015; 372: 1909-1919
        • Department of Health and Human Services, National Institutes of Health, National Cancer Institute
        Common terminology criteria for adverse events (CTCAE)v4.03.
        2010 (Avaiable at:) (Accessed December 21, 2015)
        • Eisenhauer E.A.
        • Therasse P.
        • Bogaerts J.
        • et al.
        New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1).
        Eur J Cancer. 2009; 45: 228-247
      1. Van Cutsem E, Ohtsu A, Falcone A, et al. Phase III RECOURSE trial of TAS-102 vs, placebo, with best supportive care (BSC), in patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies. Ann Oncol 25 (supply 4) 2014; 11 (Abstract LBA13).

        • Yoshino T.
        • Komatsu Y.
        • Yamada Y.
        • et al.
        Randomized phase III of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations.
        Invest New Drugs. 2015; 33: 740-750
        • Tsukihara H.
        • Nakagawa F.
        • Sakamoto K.
        • et al.
        Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts.
        Oncol Rep. 2015; 33: 2135-2142
        • Kuboki Y.
        • Nishina T.
        • Shinozaki E.
        • et al.
        An investigator initiated multicenter phase I/II study of TAS-102 with bevacizumab for metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE).
        J Clin Oncol. 2015; 33 (abstract 3544)